Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
|Articles|March 1, 2004
- Volume 0 0
Sodium Nitrite Injection
Advertisement
Hope Pharmaceuticals (Scottsdale,Ariz) recently announced the release ofSodium Nitrite Injection USP 3% in singledosevials. This product is indicated for thetreatment of cyanide poisoning. It is a primarycomponent of the Cyanide AntidoteKit, which is used by hospitals and publicsafety authorities for emergency preparedness.Cyanide inhalation can causesevere toxic effects and death within minutesto hours. Prompt treatment is criticalfor patient survival. The new vials facilitaterapid administration during an emergency.For more information, visitwww.hopepharm.com.
Articles in this issue
over 22 years ago
Interface Speeds Up Prescription Fillingover 22 years ago
New Technologies Top Surveyover 22 years ago
Partnership Addresses Packaging Solutionsover 22 years ago
PDX Software Gets High Marksover 22 years ago
Polar Powder Cold Pak with Magnetic Therapyover 22 years ago
Seal•ONover 22 years ago
SaltAire Sinus Reliefover 22 years ago
Zim's Crack Creme Hand Sanitizerover 22 years ago
CoroWise Plant Sterolsover 22 years ago
CulturelleAdvertisement
Related to this article
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5